The latest GPUs need a type of rare earth metal called Terbium and there are only 30 companies in the world exploring or producing it. Find the list for free.
To own Clarivate, you need to believe its AI-enabled, subscription-based tools can stay essential to research institutions despite funding pressure, open data, and high debt. The Abes win strengthens the case that its higher education and government-facing platforms are becoming embedded in national infrastructure, but it does little to reduce concerns about ongoing losses and the execution risk around Clarivate’s broader portfolio reshaping in the near term.
The guidance reaffirmed on July 6, 2026, for full-year revenue of US$2.30 billion to US$2.42 billion frames how meaningful the Abes contract might be in the context of Clarivate’s scale. While this single deal is unlikely to move the top line on its own, it reinforces the AI-and-SaaS catalyst that underpins those revenue expectations, in contrast to the risks tied to budget constraints and customers exploring lower cost alternatives.
Yet against this encouraging contract win, investors should also be aware that...
Read the full narrative on Clarivate (it's free!)
Clarivate's narrative projects $1.9 billion revenue and $142.7 million earnings by 2029. This assumes revenues will decrease by 7.4% yearly and requires an earnings increase of about $280 million from -$137.4 million today.
Uncover how Clarivate's forecasts yield a $2.50 fair value, a 8% upside to its current price.
Some of the lowest-estimate analysts paint a much tougher picture, expecting revenue to sit near US$2.4 billion and earnings only around US$26.8 million, so you should weigh this pessimism against contracts like Abes and consider how your own expectations compare.
Explore 4 other fair value estimates on Clarivate - why the stock might be worth just $2.40!
Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.
Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com